AR-quiver approach to affine canonical basis elements

AbstractThis is the continuation of [Y. Li, Affine quivers of type A˜n and canonical bases, math.QA/0501175]. We describe the affine canonical basis elements in the case when the affine quiver has arbitrary orientation. This generalizes the description in [G. Lusztig, Affine quivers and canonical bases, Publ. Math. Inst. Hautes Études Sci. 76 (1992) 111–163]

Flow diagram describing the review process and study selection.

<p>Flow diagram describing the review process and study selection.</p

Additional file 1: Table S1. of Estimating the number of people who inject drugs in Australia

Sex and age distributions of people who inject drugs observed in routinely collected and survey data, 2014, and summary proportions obtained by random effects meta-analysis. Sex and age distributions observed in the National Opioid Pharmacotherapy Statistical Annual Data Collection, Australian Bureau of Statistics Causes of Death data, Australian Needle and Syringe Program Survey, and Illicit Drug Reporting System, and summary proportions used to disaggregate the national estimate of people who inject drugs by sex and age. (PDF 73 kb

Additional file 1: of Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012

Table S1. ICD-10 codes used to define cause-specific mortality and hospital admissions among people with an HBV and HCV notification, NSW 1993-2012, n = 150,403. Table S2. Cause-specific mortality among people with an HBV and HCV notification, NSW 1993-2012, by ICD-10 chapter, n = 150,403. Table S3. Unadjusted analysis of factors associated with liver-related mortality among people with an HBV notification, NSW 1993-2012, n = 57,929. Table S4. Unadjusted analysis of factors associated with liver-related mortality among people with an HCV notification, NSW 1993-2012, n = 96,250. Table S5. Other cause-related mortality among people with an HBV and HCV notification, NSW 1993-2012, by ICD-10 chapter and year of birth, n = 150,403. Table S6. Adjusted analysis of factors associated with liver-related mortality among people with an HBV and HCV notification, NSW 1993-2012, n = 150,403. (DOCX 50 kb

Impact of health-related quality of life and social functioning on treatment uptake, adherence and SVR.

<p>Impact of health-related quality of life and social functioning on treatment uptake, adherence and SVR.</p

Factors associated with longitudinal social functioning score (<i>lower</i> score corresponds to <i>higher</i> functioning), (n = 146).

<p>Factors associated with longitudinal social functioning score (<i>lower</i> score corresponds to <i>higher</i> functioning), (n = 146).</p

Recent HCV treatment uptake, adherence and sustained virological response by social functioning score.

<p>(Opiate Treatment Index score 0–9, 10–14, ≥15) at baseline.</p

Characteristics of participants in Australian Trial in Acute Hepatitis C, by treatment group and HCV RNA status at baseline.

<p>Characteristics of participants in Australian Trial in Acute Hepatitis C, by treatment group and HCV RNA status at baseline.</p

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?

<div><p>Background</p><p>Widely access to interferon-free direct-acting antiviral regimens (IFN-free DAA) is poised to dramatically change the impact of the HCV epidemic among people who inject drugs (PWID). We evaluated the long-term effect of increasing HCV testing, treatment and engagement into harm-reduction activities, focused on active PWID, on the HCV epidemic in British Columbia (BC), Canada.</p><p>Methods</p><p>We built a compartmental model of HCV disease transmission stratified by disease progression, transmission risk, and fibrosis level. We explored the effect of: (1) Increasing treatment rates from 8 to 20, 40 and 80 per 1000 infected PWID/year; (2) Increasing treatment eligibility based on fibrosis level; (3) Maximizing the effect of testing by performing it immediately upon ending the acute phase; (4) Increasing access to harm-reduction activities to reduce the risk of re-infection; (5) Different HCV antiviral regimens on the Control Reproduction Number <i>R</i>_<i>c</i>. We assessed the impact of these interventions on incidence, prevalence and mortality from 2016 to 2030.</p><p>Results</p><p>Of all HCV antiviral regimens, only IFN-free DAAs offered a high chance of disease elimination (i.e. <i>R</i>_<i>c</i> < 1), but it would be necessary to substantially increase the current low testing and treatment rates. Assuming a treatment rate of 80 per 1000 infected PWID per year, coupled with a high testing rate, the incidence rate, at the end of 2030, could decrease from 92.9 per 1000 susceptible PWID per year (Status Quo) to 82.8 (by treating only PWID with fibrosis level <i>F</i>₂ and higher) or to 65.5 (by treating PWID regardless of fibrosis level). If PWID also had access to increased harm-reduction activities, the incidence rate further decreased to 53.1 per 1000 susceptible PWID per year. We also obtained significant decreases in prevalence and mortality at the end of 2030.</p><p>Conclusions</p><p>The combination of increased access to HCV testing, highly efficacious antiviral treatment and harm-reduction programs can substantially decrease the burden of the HCV epidemic among PWID. However, unless we increase the current levels of treatment and testing, the HCV epidemic among PWID in BC, and in other parts of the world with similar epidemiological background, will remain a substantial public health concern for many years.</p></div

HCV Transmission and Disease Progression Model Schematic.

<p>HCV Transmission and Disease Progression Model Schematic.</p